Gensco® Leadership Team
Gensco® is a specialty pharmaceutical manufacturer specializing in development and commercialization of prescription topically-applied transdermal products. Our capabilities allow us to quickly launch products into significant niche markets. Our Leadership Team oversees organizational goals, strategic planning development, and overall decision making.
Medical Advisory Board
We currently have relationships with key medical advisors including:
James R. Andrews, MD
Orthopedic Surgeon Andrews Sports Medicine and Orthopedic Medicine.
view biography
Gary E. Myerson, MD
Rheumatologist Arthritis & Rheumatology Georgia, P.C.
view biography
Alesia Wagner, DO, FACOFP
Associate Professor, Primary Care Touro University College of Osteopathic Medicine
view biography
Marc Alan Brenner, DPM
Podiatrist The Institute for Diabetic Foot Research
view biography
Executive Team
Our executive leadership team is comprised of proven leaders with a diverse background but the singular goal of helping us achieve our strategic vision.
Paul Zimmerman, M.D.
Chairman & CEO
view biography
Frank Aguilar
VP, National Accounts
Crystal Lore
VP Business Development
view biography
Robert L. Wilbur, Pharm.D., CPh
Executive Director, Medical Affairs
view biography
David A. Andry
Senior Director National Accounts
view biography
Lewis Archibeck
Sr. Sales Executive
Lisa Capote, Esq
General Counsel
MISSION STATEMENT
Gensco® Pharma is committed to Better Science for Health.
Our resources are focused on innovative research, the development of superior quality medications and unique delivery systems. We are an evidence-based solutions company that is progressively developing products utilizing new technologies that deliver outcomes to reduce the effects caused by disease or pathology.
GENSCO® TRENDING
Looking To The Future
RizaFilm migraine treatment launching Q5
Launching in Q4 2025, RizaFilm® delivers fast, water-free migraine relief through novel oral dissolvable film (ODF) technology—offering unmatched convenience, portability, and speed in a tablet-dominated market.
- Gensco Pharma® Acquires Global Rights and IP for RizaFilm® and RizaPort® May 13, 2025 Featured, Industry, Press Release, Product Update - Gensco Pharma acquires global rights to RizaFilm® and RizaPort®, with a U.S. migraine treatment launch… more...
- Gensco® Pharma Announces RizaFilm® Commercialization Update in the United States September 26, 2023 Featured, Industry, Press Release, Product Update - Gensco® Pharma, a specialty pharmaceutical company, in partnership with IntelGenx is announcing the anticipated launch… more...
- Skin Tears Treatment Market to Observe Strong Development by 2018-2026 April 15, 2019 Articles, Featured, Industry - [To download a printable version of this article, click here] MARKET RESEARCH April 12, 2019… more...
- Gensco® Pharma Partners with IntelGenx to Launch and Commercialize RIZAFILM® (U.S. market name for RIZAPORT® — Rizatriptin Oral Film) in the United States December 12, 2018 Featured, Industry, Press Release, Product Update - Miami, Florida, December 12, 2018 – Gensco® Pharma, a leading specialty pharmaceutical manufacturer specializing in… more...